National Path Lab
Infectious Disease & Molecular Testing

Congenital & Perinatal Infections

Certain infections acquired during pregnancy can affect the fetus or newborn. Depending on the clinical situation, laboratory evaluation may be considered for infections such as cytomegalovirus (CMV), toxoplasmosis, rubella, syphilis, hepatitis B, and HIV, among others.

The interpretation of maternal antibody and molecular results can be complex and should be performed in the appropriate clinical context, typically by an obstetrician or specialist familiar with the nuances of prenatal infection screening.

At National Path Lab (NPL), testing for congenital and perinatal infections is available to support antenatal screening and evaluation of suspected fetal or newborn infection.

Tests available
9
Tests available
Health package
1
Health package

Tests Available at NPL

TOXOPLASMA IGG

Turn Around Time
SAMPLE BY MON & THU 1:00 PM, REPORT ON SAME DAY LATE EVENING

Rs. 1400

TOXOPLASMA IGM

Turn Around Time
SAMPLE BY MON & THU 1:00 PM, REPORT ON SAME DAY LATE EVENING

Rs. 1400

CYTOMEGALOVIRUS (CMV) ANTIBODIES PANEL, IGG & IGM

Turn Around Time
SAMPLE BY MON & THU 1:00 PM, REPORT ON SAME DAY LATE EVENING

Rs. 2300

CYTOMEGALOVIRUS (CMV) DNA, QUANTITATIVE PCR

Turn Around Time
SAMPLE BY TUE 8:00 AM REPORT ON NEXT DAY EVENING

Rs. 11500

SYPHILIS ANTIBODIES (TOTAL) TREPONEMA BY EIA, SERUM

Turn Around Time
SAMPLE BY TUE AND FRI 1:00PM, REPORT SAME DAY LATE EVENING

Rs. 2300

HEPATITIS B SURFACE ANTIGEN, QUALITATIVE, SCREENING

Turn Around Time
SAMPLE DAILY BY 7:00 PM REPORT ON SAME DAY

Rs. 300

RUBELLA (GERMAN MEASLES) ANTIBODIES IGG

Turn Around Time
SAMPLE BY MON & THU 1:00 PM REPORT ON SAME DAY LATE EVENING

Rs. 1400

RUBELLA (GERMAN MEASLES) ANTIBODIES IGM

Turn Around Time
SAMPLE BY MON & THU 1:00 PM, REPORT ON SAME DAY LATE EVENING

Rs. 1400

HIV I & II ANTIBODY, SCREENING

Turn Around Time
SAMPLE DAILY BY 7:00 PM REPORT ON SAME DAY

Rs. 500

About Congenital & Perinatal Infections

Causes & Risk Factors

Congenital and perinatal infections can be transmitted from mother to baby through several routes:

•  Transplacental transmission during pregnancy — relevant to infections such as CMV, toxoplasmosis, rubella, and syphilis.

•  Transmission during delivery — relevant to infections such as hepatitis B, HIV, and certain other pathogens present in maternal blood or genital secretions.

•  New or first-time maternal infection during pregnancy generally carries higher transmission risk to the fetus than infection acquired before pregnancy, for several of these organisms.

•  Lack of routine antenatal screening, which may leave a maternal infection undetected and untreated during pregnancy.

Symptoms & When to Test

Maternal infection is often asymptomatic, while newborn signs vary depending on the specific infection and timing of transmission.

•  Maternal infection is frequently asymptomatic or causes only mild, nonspecific symptoms, which is why screening (rather than symptom-based testing alone) is important during pregnancy

•  Newborn signs may include growth restriction, jaundice, skin rash, hearing or vision problems, or other findings identified at or after birth

•  Some congenital infections may not become apparent until later in infancy or childhood

When Should You Consider Testing?

Maternal screening is generally recommended as part of routine antenatal care, according to established protocols. Additional or repeat testing may be considered with specific risk factors, known exposure during pregnancy, or abnormal findings on prenatal ultrasound.

Why Tests Are Combined

Several congenital infections are often screened together (sometimes referred to informally as a "TORCH"-type panel) because their consequences for the fetus can overlap in presentation, and identifying maternal infection status for several organisms at once is often more efficient during routine antenatal screening than testing sequentially based on symptoms that may never appear.

Interpreting maternal antibody results (IgG vs. IgM, and timing relative to pregnancy) requires care, since the presence of IgG may reflect immunity from a past infection (generally reassuring) rather than a new, active infection during the current pregnancy (which carries different implications) — this distinction is central to correct interpretation and is best made by a specialist.

When a newborn is suspected to have a congenital infection, testing the newborn directly (rather than relying only on maternal results) may be needed to confirm active infection, since maternal antibodies can cross the placenta and be present in a newborn's blood without indicating actual newborn infection.

Tests Available at NPL

Test Code

Test

Clinical Relevance

I0027

CYTOMEGALOVIRUS (CMV) ANTIBODIES PANEL, IGG

& IGM

Assesses maternal CMV status; interpretation of IgG/IgM results requires clinical context.

I0098 & I0099

Toxoplasmosis Testing

Assesses maternal toxoplasmosis status, relevant given potential fetal implications of a new infection during pregnancy.

I0131 & I0132

Rubella Testing

Assesses maternal rubella immunity or infection status.

I0013

Syphilis Testing

Screens for maternal syphilis, an important and treatable cause of congenital infection when detected and treated promptly.

S0010,S0013

Hepatitis B & HIV Testing

Routine antenatal screening, relevant to preventing mother-to-child transmission with appropriate management.

N0010

CYTOMEGALOVIRUS (CMV) DNA, QUANTITATIVE

PCR

 

Most infectious-disease molecular tests and microbiological investigations do not require fasting. However, some blood tests ordered at the same time may have specific preparation requirements. Please follow the instructions provided by your doctor or NPL.

Home Sample Collection

Maternal blood testing for congenital infection screening can typically be arranged through NPL's standard home sample collection service.

Newborn testing for suspected congenital or perinatal infection is generally performed in a hospital or neonatal care setting by specialist staff, given the clinical urgency and specific handling requirements — this is not a home collection service.

Reports are delivered securely to your treating obstetrician or pediatrician, and to you, within the timeframe specified for the tests ordered.

When to See a Doctor

•  As part of routine antenatal care — discuss recommended screening with your obstetrician

•  Known exposure to an infection (such as rubella or toxoplasmosis) during pregnancy

•  Abnormal findings on prenatal ultrasound suggestive of possible infection

•  A newborn with signs suggestive of congenital infection — evaluated promptly by a pediatrician

Medical Disclaimer

Laboratory tests support the evaluation of congenital and perinatal infections but require careful interpretation by a qualified obstetrician or pediatrician together with clinical and pregnancy history. This content is for general information only and is not a substitute for medical advice, diagnosis, or treatment.

Related Packages

BASIC STI PROFILE

Test Includes
11 Tests

Rs. 8800

Frequently Asked Questions

Not necessarily. A positive IgG often indicates past infection and immunity, while IgM more typically suggests a recent or current infection. Interpretation depends on the specific infection, timing, and clinical context, and is best done by your obstetrician.
Screening recommendations vary by infection and by local antenatal care protocols. Your obstetrician can advise which tests are recommended as part of your routine antenatal care.
No, maternal blood testing for congenital infection screening does not require fasting.
Some congenital infections (such as syphilis) can be effectively treated during pregnancy to reduce risk to the baby, while management of others depends on the specific infection and timing. Your obstetrician can discuss appropriate management if a maternal infection is identified.
Because maternal antibodies can cross the placenta and appear in newborn blood without indicating actual infection in the baby, direct newborn testing may be needed to confirm or exclude active infection when clinically suspected.